13F Holdings
中文EN

GLSI Greenwich LifeSciences, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1799788 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-27.9%
TTM EPS YoY-14.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-107,371.7%
ROA-481.0%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets129.6%
Debt / equity—
Current ratio0.77x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.55x
Accruals ratio-217.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$17.22M$15.48M$7.70M$6.48M$3.56M
SG&A expense$2.23M$2.16M$1.63M$1.56M$1.04M
Operating income-$19.45M-$17.64M-$9.33M-$8.04M-$4.60M
Net income-$19.36M-$17.41M-$8.89M-$7.83M-$4.57M
EPS (basic)-1.43-1.34-0.69-0.61-0.35
EPS (diluted)-1.43-1.34-0.69-0.61-0.35
Weighted avg. shares (diluted)13.53M13.01M12.85M12.91M12.94M
Balance sheet
Cash & equivalents$6.18M$4.09M$6.99M$13.47M$27.20M
Current assets$6.18M$4.09M———
Intangibles—$1,779$5,391$9,003$12,615
Total assets$6.18M$4.09M$6.99M$13.48M$27.22M
Current liabilities$5.82M$3.19M$294,406$262,905$385,172
Total liabilities$5.82M$3.19M$294,406$262,905$385,172
Shareholders' equity$353,217$908,626$6.70M$13.21M$26.83M
Shares outstanding14.30M13.15M12.85M12.85M13.15M
Cash flow statement
Operating cash flow-$9.91M-$7.27M-$6.48M-$6.20M-$4.29M
Financing cash flow$12.00M$4.37M—-$7.54M$2.84M
Stock-based compensation$6.80M$7.25M$2.38M$1.74M$660,582
Share buybacks———$7.54M—

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.